Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to $72.7 million.

  • Mimedx's Operating Expenses rose 2883.01% to $72.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $268.1 million, marking a year-over-year increase of 1675.43%. This contributed to the annual value of $237.4 million for FY2024, which is 609.46% up from last year.
  • As of Q3 2025, Mimedx's Operating Expenses stood at $72.7 million, which was up 2883.01% from $67.5 million recorded in Q2 2025.
  • In the past 5 years, Mimedx's Operating Expenses ranged from a high of $72.7 million in Q3 2025 and a low of $45.1 million during Q4 2022
  • In the last 5 years, Mimedx's Operating Expenses had a median value of $57.7 million in 2021 and averaged $57.6 million.
  • Within the past 5 years, the most significant YoY rise in Mimedx's Operating Expenses was 4565.52% (2021), while the steepest drop was 1040.08% (2021).
  • Mimedx's Operating Expenses (Quarter) stood at $46.7 million in 2021, then fell by 3.45% to $45.1 million in 2022, then increased by 25.89% to $56.8 million in 2023, then rose by 13.79% to $64.6 million in 2024, then grew by 12.52% to $72.7 million in 2025.
  • Its Operating Expenses stands at $72.7 million for Q3 2025, versus $67.5 million for Q2 2025 and $63.3 million for Q1 2025.